AstraZeneca made a $10 billion offer for Rhythm Pharmaceuticals, WSJ reports
The reported bid would be a sizable bolt-on for AstraZeneca's rare disease and obesity pipeline and follows a wave of large pharma M&A.
WSJ · +13 outlets
Novo Nordisk hikes 2026 outlook again as Wegovy pill rollout accelerates
The third guidance lift reflects strong oral GLP-1 demand, with Novo also eyeing a US launch of the combination drug Cagrisema.
Reuters · +5 outlets
Eli Lilly widens GLP-1 lead over Novo Nordisk with nearly double the sales
Lilly's incretin franchise continues to outpace Novo Nordisk in the market for obesity and diabetes drugs.
MedWatch · +3 outlets
Pfizer raises 2026 forecasts as Eliquis and cancer drugs offset falling Covid sales
Newer products are filling the revenue gap left by declining demand for Pfizer's Covid franchise.
Reuters · +13 outlets
Madrigal's former clinical development head files whistleblower suit alleging Rezdiffra safety cover-up
The lawsuit raises questions about safety disclosures for Madrigal's liver disease drug, its key commercial asset.
Fierce Pharma · +2 outlets
Biopharma stocks likely to climb higher after 'blue wave,' analysts say
Analysts expect a friendlier policy backdrop for drugmakers following the election results.
BioPharma Dive · +5 outlets
Lilly's Jaypirca wins FDA approval for first-line CLL/SLL treatment
The label expansion moves the BTK inhibitor into frontline use for chronic lymphocytic leukemia and small lymphocytic lymphoma.
scanx.trade · +5 outlets
Celltrion says 4-hormone obesity drug beats Lilly's retatrutide in preclinical study
The Korean company reports better weight loss and muscle preservation in animals, with a US trial planned for 2027.
조선일보 · +3 outlets
CVS Health to split in two; Bayer weighs most-favored-nation pricing
Pharma Pulse rounds up major industry developments including a planned breakup of CVS Health.
Pharmaceutical Commerce
Seres reports 12 of 15 patients with cancer-treatment-related bowel inflammation improved without immune suppressants
The company plans a prevention study in colitis tied to cancer immunotherapy.
Stock Titan · +6 outlets
Switzerland faces pressure from US drug pricing policy
US pricing measures are rippling into Swiss pharma's home market and trade relations.
SWI swissinfo.ch · +4 outlets
CAPR stock rises as trial investigators urge FDA to approve Deramiocel
Investigators wrote to the FDA supporting approval of Capricor's cell therapy for Duchenne muscular dystrophy.
Yahoo Finance · +2 outlets
Radiopharm says brain scan matched MRI 93% of the time, plans ~280-patient trial
The imaging agent could offer an alternative to MRI for brain imaging in a planned larger study.
Stock Titan · +1 outlets
Precigen's treatment has started in over 500 patients for a disease long managed by repeated surgery
The company reports growing uptake of its therapy for recurrent respiratory papillomatosis.
Stock Titan · +4 outlets
Korean obesity drug race intensifies as Epe launches, with GLP-1, muscle and patch therapies in development
Korean drugmakers are advancing a broad set of obesity candidates amid global GLP-1 demand.
헬스조선 · +1 outlets
Hospitals can now use a children's kidney therapy without joining the study registry
Regulatory change broadens access to the pediatric kidney therapy outside a registry requirement.
Stock Titan
BioCryst reports third quarter 2026 financial results
The rare disease drugmaker posted quarterly results.
GlobeNewswire · +1 outlets
Summit Therapeutics reports financial results and operational updates
The company reported quarterly results amid ongoing development of its oncology pipeline.
Quantisnow · +1 outlets